SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024. Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. T ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Maryland on behalf of those who acquired Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) securities during the period of November 7, 2024 to June 26, 2024, inclusive ("the Class Period"). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elanco between November 7, 2023 and June 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 19, 2024 /PRNewswir ...

文章核心观点 - 领先的证券法律事务所Bleichmar Fonti & Auld LLP宣布已对Elanco Animal Health Incorporated(纽交所代码:ELAN)及其高管提起诉讼,指控其可能违反联邦证券法 [1] - 该诉讼指控Elanco公司就其两款重要治疗药物Zenrelia和Credelio Quattro的FDA审批情况向投资者作出了虚假或误导性陈述 [2][3] - 2024年6月27日,Elanco公司宣布FDA将不会在6月批准这两款药物,并且Zenrelia将带有安全性警示,导致公司股价下跌超过21% [3] 根据目录分别总结 诉讼概况 - Bleichmar Fonti & Auld LLP代表Elanco公司投资者提起诉讼,指控公司及高管可能违反联邦证券法 [1] - 投资者有至2024年12月6日的期限向法院申请担任该案的首席原告 [1] - 该案件正在美国马里兰州地区法院审理,案号为Barpar v. Elanco Animal Health Incorporated, et al., No. 24-cv-02912 [1] 诉讼内容 - Elanco公司开发用于治疗动物疾病的产品,其中两款重要的治疗药物正在接受FDA审批 [2] - 公司曾表示FDA拥有完成审批所需的全部数据,预计在2024年6月底前获批 [2] - 但2024年6月27日,Elanco公司宣布FDA将不会在6月批准这两款药物,且Zenrelia将带有安全性警示 [3] 股价影响 - 受此消息影响,Elanco公司股价从2024年6月26日的17.97美元下跌超过21%至6月27日的14.27美元 [3] - 律所正在调查Elanco公司及其高管是否就FDA药品审批情况向投资者作出了虚假或误导性陈述 [3]

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2024. So what: If you purchased Elanco Animal Health Incorporated ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Elanco Animal Health Incorporated (ELAN) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider. This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 27 ...

SAN FRANCISCO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Elanco Animal Health (NYSE: ELAN) is facing a securities class action lawsuit alleging the company misled investors about the safety and regulatory path of its new dermatology drug, Zenrelia. Hagens Berman urges Elanco investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024 Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: ELAN@hbsslaw.com 844-916-0895 ...

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=108706&fro ...